Project Details
Description
SUMMARY
Phosphatidate (PA) phosphatase (PAP) is an evolutionarily conserved enzyme that plays a key role in lipid
homeostasis by controlling the cellular levels of its substrate, PA, and its product, diacylglycerol. These lipids are
essential intermediates for the synthesis of triacylglycerol and membrane phospholipids; they also function in
phospholipid synthesis gene expression, lipid droplet formation, and vesicular trafficking. The importance of PAP
to lipid homeostasis and cell physiology is exemplified in yeast, mouse, and human by a host of cellular defects
and lipid-based diseases associated with loss or overexpression of enzyme function. In yeast, loss of Pah1 PAP
results in a massive expansion of the nuclear/ER membrane; this is ascribed to increases in PA content and
phospholipid synthesis that occur at the expense of triacylglycerol synthesis. The increase in phospholipid
synthesis is associated with the derepression of phospholipid synthesis gene expression, whereas the reduction
in the synthesis of triacylglycerol is associated with a decrease in lipid droplet formation. Lipin PAP deficiency
in mouse and human causes rhabdomyolysis, and deficiency in the mouse is also characterized by hepatic
steatosis during the neonatal period, lipodystrophy, insulin resistance and peripheral neuropathy. The
overexpression of lipin 1 PAP in mouse results in increased lipogenesis and obesity. Human lipin 2 PAP
deficiency causes chronic recurrent multifocal osteomyelitis and congenital dyserythropoietic anemia, whereas
genetic variations in the human LPIN2 PAP gene are associated with type 2 diabetes. PAP is a peripheral
membrane protein that must translocate from the cytosol to the nuclear/ER membrane in order to convert PA to
diacylglycerol. This conserved process is governed by phosphorylation/dephosphorylation of the enzyme. In
the cytosol, PAP is phosphorylated by multiple protein kinases that causes its retention in this cellular
compartment. The membrane association of PAP requires is dephosphorylation by a conserved protein
phosphatase complex (e.g., Nem1-Spo7 in yeast, CTDNEP1-NEP1-R1 in mouse and human). Besides its
location, the phosphorylation of PAP inhibits its activity but stabilizes it to proteasomal degradation;
dephosphorylation has the opposite effects. The work proposed in this MIRA application, which builds on our
prior work made possible by the advantages of the yeast model, will gain understanding into the structure-
function, mode of action and phosphorylation/dephosphorylation-mediated regulations of Pah1 PAP and the
Nem1-Spo7 protein phosphatase complex. We will pursue rigorous experimental approaches that combine
biochemistry and molecular genetics to shed light on how the proportional synthesis of triacylglycerol and
membrane phospholipids is controlled. Based on the conserved nature of the Nem1-Spo7/Pah1 phosphatase
cascade, the information gained from our studies with yeast is expected to be relevant in human.
Status | Finished |
---|---|
Effective start/end date | 6/1/20 → 5/31/24 |
Funding
- National Institute of General Medical Sciences: $652,774.00
- National Institute of General Medical Sciences: $653,120.00
- National Institute of General Medical Sciences: $653,120.00